| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 10/29/266:45 AM | $6.36 | $7.48 | +17.6% | +7% | $22.51B | $24.40B | +8.4% | +39% | |
| Q2 '26 | 8/5/266:45 AM | $6.01 | $8.38 | +39.4% | +33% | $20.44B | $22.97B | +12.4% | +48% | |
| Q1 '26 | 4/30/266:45 AM | $6.85 | $8.55 | +24.8% | +156% | $17.78B | $19.80B | +11.4% | +56% | |
| Q4 '25 | 2/4/266:45 AM | $6.96 | $7.54 | +8.3% | +42% | $17.91B | $19.30B | +7.7% | +43% | |
| Q3 '25 | 10/30/256:45 AM | $5.96 | $7.02 | +17.8% | ⚠ Check | $16.05B | $17.60B | +9.7% | +54% | |
| Q2 '25 | 8/7/256:45 AM | $5.60 | $6.31 | +12.7% | +61% | $14.70B | $15.56B | +5.8% | +38% | |
| Q1 '25 | 5/1/256:45 AM | $3.02 | $3.34 | +10.6% | +29% | $12.66B | $12.73B | +0.5% | +45% |
⚠ Potential error in calculation, check manually. The two EPS figures may be on different share counts (a stock split one source has not adjusted for).